摘要
目的:研究虎杖苷对肝纤维化的治疗作用。方法:使用腹腔注射CCl4构建C57小鼠的肝纤维化模型,同时采用虎杖苷腹腔注射进行治疗。检测血清ALT水平以判断肝脏损伤情况,运用组织病理观察和天狼猩红染色观察肝纤维化情况,使用人源肝星状细胞系LX-2细胞给药干预后采用Western blot检测TGF-β1和α-SMA蛋白的表达情况。结果:相较于CCl4组,虎杖苷治疗组小鼠血清ALT水平明显降低,差异具有统计学意义(P<0.05)。虎杖苷显著下调LX-2细胞系中TGF-β1和α-SMA的蛋白表达。结论:虎杖苷具有良好的抗肝纤维化作用,其作用可能与抑制TGF-β1有关。
Objective: To investigate the pharmacological effects of polydatin about the treatment of liver fibrosis. Methods: C57 mice were used to induce liver fibrosis model by injecting CC14 intraperitoneally. For the treatment group,mice were treated with in- traperitoneal injection of polydatin. Using serum ALT to determine liver injury, pathological staining and Sirius red staining were ap- plied to determine liver fibrosis. Using human hepatic stellate cells line LX-2 to administrate polydatin and using Western blot to de- tect the protein expression of TGF-131 and c^-SMA. Results : Compared with CC14 group, ALT in polydatin group marked reduced. Polydatin significantly reduced the protein expression levels of TGF-t31 and a-SMA in the LX-2 cell line. Conclusion : Polydatin can significantly ameliorate liver fibrosis and this effect may depend on the inhibition of TGF-β1.
出处
《亚太传统医药》
2017年第16期14-16,共3页
Asia-Pacific Traditional Medicine
基金
广东省自然科学基金重点项目(2016A030311014)
兰州大学附属第一医院院内基金(ldyyyn2015-17)
关键词
虎杖苷
肝纤维化
TGF-Β1
Α-SMA
Polydatin
Hepatic Fibrosis
Transforming Growth Factor-β1
α-smooth Muscle Actin